IRIS
PIERANTOZZI, MARIANGELA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 50.798
AS - Asia 9.387
EU - Europa 8.316
SA - Sud America 907
AF - Africa 90
Continente sconosciuto - Info sul continente non disponibili 24
OC - Oceania 15
Totale 69.537
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 50.616
SG - Singapore 6.513
IT - Italia 3.797
CN - Cina 1.030
RU - Federazione Russa 770
BR - Brasile 758
DE - Germania 675
UA - Ucraina 642
HK - Hong Kong 615
IE - Irlanda 512
FR - Francia 500
VN - Vietnam 467
NL - Olanda 321
GB - Regno Unito 319
FI - Finlandia 187
JP - Giappone 168
PL - Polonia 159
SE - Svezia 156
KR - Corea 143
CA - Canada 106
IN - India 94
AR - Argentina 62
ID - Indonesia 57
BD - Bangladesh 49
TR - Turchia 47
MX - Messico 44
IQ - Iraq 43
AT - Austria 41
ZA - Sudafrica 37
BE - Belgio 35
CH - Svizzera 33
ES - Italia 27
EU - Europa 21
GR - Grecia 21
EC - Ecuador 20
PK - Pakistan 20
CZ - Repubblica Ceca 19
UZ - Uzbekistan 16
RO - Romania 15
SA - Arabia Saudita 15
VE - Venezuela 15
AL - Albania 14
MA - Marocco 14
CO - Colombia 13
PY - Paraguay 13
AE - Emirati Arabi Uniti 12
AU - Australia 12
AZ - Azerbaigian 11
CL - Cile 11
LT - Lituania 11
IL - Israele 10
JM - Giamaica 10
MY - Malesia 10
EG - Egitto 9
KG - Kirghizistan 9
HR - Croazia 7
KE - Kenya 7
NP - Nepal 7
PE - Perù 7
PH - Filippine 7
PT - Portogallo 7
SM - San Marino 7
TN - Tunisia 7
TW - Taiwan 7
BO - Bolivia 6
KZ - Kazakistan 6
SK - Slovacchia (Repubblica Slovacca) 6
DK - Danimarca 5
IR - Iran 5
LB - Libano 5
RS - Serbia 5
BY - Bielorussia 4
DO - Repubblica Dominicana 4
JO - Giordania 4
BG - Bulgaria 3
HU - Ungheria 3
MD - Moldavia 3
NG - Nigeria 3
NZ - Nuova Zelanda 3
PA - Panama 3
PS - Palestinian Territory 3
SI - Slovenia 3
TH - Thailandia 3
TT - Trinidad e Tobago 3
AM - Armenia 2
AO - Angola 2
DM - Dominica 2
DZ - Algeria 2
GE - Georgia 2
HN - Honduras 2
KH - Cambogia 2
LU - Lussemburgo 2
LV - Lettonia 2
OM - Oman 2
SN - Senegal 2
UY - Uruguay 2
A2 - ???statistics.table.value.countryCode.A2??? 1
BA - Bosnia-Erzegovina 1
BB - Barbados 1
BM - Bermuda 1
Totale 69.515
Salva come PNG Salva come JPEG
Città #
Woodbridge 13.667
Wilmington 13.036
Houston 11.883
Fairfield 1.734
Singapore 1.557
Ann Arbor 1.069
Ashburn 1.067
San Jose 700
Hong Kong 611
Seattle 608
Cambridge 593
Chandler 592
Jacksonville 574
Rome 548
Dublin 473
Beijing 396
Medford 358
Milan 335
Santa Clara 266
The Dalles 257
Dearborn 230
New York 210
Council Bluffs 177
Los Angeles 170
Lawrence 167
Tokyo 150
Lauterbourg 146
Ho Chi Minh City 138
Hanoi 123
Moscow 116
Buffalo 115
Kraków 111
San Diego 96
Florence 72
Naples 72
London 71
Munich 71
Menlo Park 69
São Paulo 67
Turin 64
Dallas 61
Verona 55
Helsinki 52
North Bergen 51
Bologna 49
Chicago 46
Nuremberg 42
Shanghai 39
Norwalk 38
Phoenix 38
Warsaw 37
Brooklyn 36
Genoa 36
Mülheim 36
Toronto 36
Zhengzhou 36
Durham 35
Orem 34
Falls Church 33
Jakarta 33
Redondo Beach 33
Redwood City 32
Brussels 31
Chennai 31
Montreal 30
Atlanta 27
Johannesburg 27
Stockholm 27
Padova 26
Amsterdam 25
Boardman 25
Boston 24
Mountain View 24
Frankfurt am Main 23
Modena 23
Rio de Janeiro 23
Palo Alto 22
Sassari 22
Trento 22
Bari 21
Denver 21
Manchester 21
Nanjing 21
Seoul 21
St Louis 20
Salt Lake City 19
University Park 19
Belo Horizonte 18
Bolzano 18
Catania 18
Da Nang 18
Hefei 18
Mexico City 17
Reggio Emilia 17
Shenzhen 17
Brasília 16
Kunming 16
Colorado Springs 15
Dhaka 15
Palermo 15
Totale 54.460
Salva come PNG Salva come JPEG
Nome #
Quality of life in Parkinson’s disease: Italian validation of the Parkinson’s Disease Questionnaire (PDQ-39-IT) 3.121
malattia di alzheimer e altre demenze diagnosi e terapia integrata. 804
Different TMS patterns of intracortical inhibition in early onset Alzheimer dementia and frontotemporal dementia 615
Strength and weaknesses of cerebrospinal fluid biomarkers in Alzheimer's disease and possible detection of overlaps with frailty process 610
Reasons driving treatment modification in Parkinson's disease: results from the cross-sectional phase of the REASON study. 599
Deep brain stimulation of CM/PF of thalamus could be the new elective target for tremor in advanced Parkinson's Disease? 597
The impact of rotigotine on cardiovascular autonomic function in early Parkinson's disease 594
Tetrabenazine improves levodopa-induced peak-dose dyskinesias in patients with Parkinson's disease 592
Therapy for dyskinesias in Parkinson’s disease patients 587
Pathological gambling from dopamine agonist and deep brain stimulation of the nucleus tegmenti pedunculopontine 586
Different patterns of nigrostriatal degeneration in tremor type versus the akinetic-rigid and mixed types of Parkinson's disease at the early stages: molecular imaging with 123I-FP-CIT SPECT 585
Rasagiline effect on bladder disturbances in early mild Parkinson's disease patients 570
Subdyskinetic apomorphine responses in globus pallidus and subthalamus of parkinsonian patients: lack of clear evidence for the 'indirect pathway' 564
Motor and non-motor effects of PPN-DBS in PD patients: insights from intra-operative electrophysiology 549
The effect of deep brain stimulation on the frontal N30 component of somatosensory evoked potentials in advanced Parkinson's disease patients 542
Successful subthalamic stimulation, but levodopa-induced dystonia, in a genetic Parkinson's disease 541
Reduced GABA Content in the Motor Thalamus during effective deep brain stimulation of the subthalamic nucleus 537
Sleep episodes and daytime somnolence as result of individual susceptibility to different dopaminergic drugs in a PD patient: a polysomnographic study 522
Multi-target strategy for Parkinsonian patients: the role of deep brain stimulation in the centromedian-parafascicularis complex. 519
123I-FP-CIT in progressive supranuclear palsy and in Parkinson's disease: a SPECT semiquantitative study 509
Effects of deep brain stimulation of the peduncolopontine area on working memory tasks in patients with Parkinson's disease 506
AD with subcortical white matter lesions and vascular dementia: CSF markers for differential diagnosis. 505
Spontaneous sleep modulates the firing pattern of Parkinsonian subthalamic nucleus 503
Intensity-dependent facial emotion recognition and cognitive functions in Parkinson's disease 500
AD with subcortical white matter lesions and vascular dementia: CSF markers for differential diagnosis 492
Cerebrospinal-fluid Alzheimer's Disease Biomarkers and Blood-Brain Barrier Integrity in a natural population of cognitive intact Parkinson's Disease patients. 491
Bilateral deep brain stimulation of the pedunculopontine and subthalamic nuclei in severe Parkinson's disease 489
Autonomic Function Tests and MIBG in Parkinson's Disease: Correlation to Disease Duration and Motor Symptoms 483
CSF biomarkers, impairment of cerebral hemodynamics and degree of cognitive decline in Alzheimer's and mixed dementia 482
The clinical efficacy of L-DOPA and STN-DBS share a common marker: reduced GABA content in the motor thalamus. 480
High endogenous cannabinoid levels in the cerebrospinal fluid of untreated Parkinson's disease patients 480
Homovanillic acid in CSF of mild stage Parkinson's disease patients correlates with motor impairment 478
Cortical hyperexcitability in post-traumatic stress disorder secondary to minor accidental head trauma: a neurophysiologic study 472
Sad and happy facial emotion recognition impairment in progressive supranuclear palsy in comparison with Parkinson's disease 471
Increased blood-cerebrospinal fluid transfer of albumin in advanced Parkinson's disease 471
Curariform peripheral block of muscular tone selectively increases precentral N30 somatosensory evoked potentials component. A pharmacological study carried out on healthy subjects and parkinsonian syndromes 470
Tetrabenazine improves levodopa-induced peak-dose dyskinesias in patients with Parkinson's disease 468
Biochemical and electrophysiological changes of substantia nigra pars reticulata driven by subthalamic stimulation in patients with Parkinson's disease 467
Cardiac sympathetic denervation is not related to nigrostriatal degeneration in Parkinson's disease 466
Microdialysis in Parkinsonian patient basal ganglia: acute apomorphine-induced clinical and electrophysiological effects not paralleled by changes in the release of neuroactive amino acids 466
The effect of levodopa therapy on dopamine transporter SPECT imaging with 123I-FP-CIT in patients with Parkinson's disease 464
SEPs N30 amplitude in Parkinson's disease and in pharmacologically induced rigidity: relationship with the clinical status 463
Efficacy and safety profile of prolonged release oxycodone in combination with naloxone (OXN PR) in Parkinson’s disease patients with chronic pain 462
Electrophysiological evidence for visuocognitive dysfunction in younger non Caucasian patients with Parkinson's disease 461
Perfusion-weighted dynamic susceptibility (DSC) MRI: basal ganglia hemodynamic changes after apomorphine in Parkinson's disease 454
Magnetic resonance imaging markers of Parkinson's disease nigrostriatal signature 453
The early course of affective and cognitive symptoms in de novo patients with Parkinson's disease 452
Serotonin impairment in CSF of PD patients, without an apparent clinical counterpart 447
Adherence to anti-Parkinson drug therapy in the "rEASON" sample of Italian patients with Parkinson's disease: The linguistic validation of the Italian version of the "morisky Medical Adherence scale-8 items" 447
123I-FP-CIT semi-quantitative SPECT detects preclinical bilateral dopaminergic deficit in early Parkinson's disease with unilateral symptoms 446
Deep brain stimulation of pedunculopontine tegmental nucleus: role in sleep modulation in advanced Parkinson disease patients: one-year follow-up. 445
Optic Nerve dysfunction in obstructive sleep apnea: An electrophysiological study 445
May a suspicious psychiatric disorder hide sporadic hemiplegic migraine? Genetic test as prompting factor for diagnosis 444
Age and stage dependency of P300 latency alterations in non-demented Parkinson's disease patients without therapy 441
A mixed D1 and D2 antagonist does not replay pattern electroretinogram alterations observed with a selective D2 antagonist in normal humans: relationship with Parkinson's disease pattern electroretinogram alterations 441
The clinical efficacy of L-DOPA and STN-DBS share a common marker: reduced GABA content in the motor thalamus 441
Helicobacter pylori-induced reduction of acute levodopa absorption in Parkinson's disease patients 440
Involvement of Subcortical Brain Structures During Olfactory Stimulation in Multiple Chemical Sensitivity 439
Bilateral GPi DBS is useful to reduce abnormal involuntary movements in advanced Parkinson's disease patients, but its action is related to modality and site of stimulation 438
Restless legs syndrome and poliomyelitis: New evidences of an old observation? 438
Effect of Vigabatrin on motor responses to transcranial magnetic stimulation: An effective tool to investigate in vivo GABAergic cortical inhibition in humans 436
CSF and clinical hallmarks of subcortical dementias: focus on DLB and PDD 436
Cerebrospinal fluid lactate levels and brain [18F]FDG PET hypometabolism within the default mode network in Alzheimer’s disease 435
Temporal administration of entacapone with slow release L-dopa: pharmacokinetic profile and clinical outcome 434
Helicobacter pylori eradication and l-dopa absorption in patients with PD and motor fluctuations 433
Pedunculopontine nucleus stimulation influences REM sleep in Parkinson's disease 432
Effect of cabergoline added to levodopa treatment on sleep-wake cycle in idiopathic Parkinson's disease: an open label 24-hour polysomnographic study 432
An electrophysiological study of D2 dopaminergic actions in normal human retina: a tool in Parkinson's disease 432
Stimulation of the subthalamic nucleus compared with the globus pallidus internus in patients with Parkinson disease 428
Deep brain stimulation of both subthalamic nucleus and internal globus pallidus restores intracortical inhibition in Parkinson's disease paralleling apomorphine effects: a paired magnetic stimulation study 427
Alexithymia is a non-motor symptom of Parkinson disease 423
Subthalamic stimulation activates internal pallidus: evidence from cGMP microdialysis in PD patients 422
Effect of apomorphine on cortical inhibition in Parkinson's disease patients: a transcranial magnetic stimulation study 421
Microdialysis in Parkinsonian patient basal ganglia: acute apomorphine-induced clinical and electrophysiological effects not paralleled by changes in the release of neuroactive amino acids 419
Visual alterations in de novo Parkinson's disease: pattern electroretinogram latencies are more delayed and more reversible by levodopa than are visual evoked potentials 418
Sleep-wake cycle and effects of cabergoline monotherapy in de novo Parkinson's disease patients - An ambulatory polysomnographic study 411
Effective treatment of restless legs syndrome by safinamide in Parkinson's disease patients 410
Catecholamine-based treatment in AD patients: expectations and delusions 408
Rotigotine effect on sleep in a de novo Parkinson's Disease patient affected by periodic limb movement disorder 407
Different patterns of cardiac sympathetic denervation in tremor-type compared to akinetic-rigid-type Parkinson's disease: molecular imaging with ¹²³I-MIBG. 406
Deep brain stimulation of the pedunculopontine tegmentum and subthalamic nucleus: effects on gait in Parkinson's disease 404
Does pattern electroretinogram spatial tuning alteration in Parkinson's disease depend on motor disturbances or retinal dopaminergic loss? 402
Emotional processing in Parkinson's disease. A study using functional transcranial doppler sonography 402
A non-comparative assessment of tolerability and efficacy of duloxetine in the treatment of depressed patients with Parkinson's disease 400
CSF markers in Alzheimer disease patients are not related to the different degree of cognitive impairment 399
Neurological complications of pregnancy 399
Deep brain stimulation in Parkinson's disease patients: biochemical evidence 398
Bilateral deep brain stimulation of the pedunculopontine and subthalamic nuclei in severe Parkinson's disease. 394
Helicobacter pylori eradication and l-dopa absorption in patients with PD and motor fluctuations.(Reply from the authors) 394
N30 wave amplitude of somatosensory evoked potentials from median nerve in Parkinson's disease: a pharmacological study 391
Psychiatric profile of motor subtypes of de novo drug-naïve Parkinson's disease patients 391
Rotigotine may improve sleep architecture in Parkinson's disease: a double-blind, randomized, placebo-controlled polysomnographic study. 390
L-dopa modulates motor cortex excitability in Alzheimer's disease patients 387
Restless legs syndrome and post polio syndrome: a case-control study 386
Low frequency stimulation of the nucleus tegmenti pedunculopontini increases cortical metabolism in parkinsonian patients 386
P3 components evoked by unilateral and bilateral somatosensory stimulation: normative data for the study of neglect syndrome 385
Decreased plasma and cerebrospinal fluid content of neuroactive steroids in Parkinson's disease 384
Long term effects of Helicobacter pylori eradication on L-dopa absorption in Parkinson's disease 382
The visuo-cognitive and motor effect of amantadine in non-Caucasian patients with Parkinson's disease. A clinical and electrophysiological study 381
Neuropsychiatric and cognitive profile of early Richardson's syndrome, Progressive Supranuclear Palsy-parkinsonism and Parkinson's disease 379
Totale 49.048
Salva come PNG Salva come JPEG
Categoria #
all - tutte 154.679
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 154.679
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021616 0 0 0 0 0 0 0 0 0 168 366 82
2021/20221.972 64 246 96 74 67 130 316 88 114 132 146 499
2022/20231.905 209 129 69 209 138 455 176 97 149 36 145 93
2023/20241.698 123 56 109 104 149 199 147 256 69 132 104 250
2024/20259.692 218 1.116 601 455 249 444 437 388 571 553 2.637 2.023
2025/20268.200 716 327 995 795 797 308 1.160 1.213 969 920 0 0
Totale 70.450